Morepen Laboratories Limited — Important, 06-08-2025: General Updates

Morepen Laboratories' board approved Q1 FY26 financial results. Consolidated revenue was Rs 425.24 Cr with a net profit of Rs 11.41 Cr. Standalone revenue was Rs 391.28 Cr, profit Rs 8.06 Cr. The company's stake in Dr. Morepen Limited dropped from 80% to 19.94% post-period due to a Rs 30.65 Cr sale and a Rs 153.01 Cr share issue for Groom Town Private Limited acquisition, changing its accounting from subsidiary to investment. A record date for dividends was set for August 30, 2025. The board also approved extending time for hiving off the Medical Devices Business to Morepen Medipath, and re-appointed Mr. Sanjay Suri as Whole-Time Director for three years.